IMMUNITYBIO, INC. Other Noncash Income (Expense)
IMMUNITYBIO, INC. (IBRX) reported Other Noncash Income (Expense) of $62.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-04
- IMMUNITYBIO, INC. other noncash income (expense) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. other noncash income (expense) for the quarter ending 2026-03-31 was $62.00K, a 0.00% change year-over-year.
- IMMUNITYBIO, INC. other noncash income (expense) for the quarter ending 2025-12-31 was $63.00K.
- IMMUNITYBIO, INC. other noncash income (expense) for the quarter ending 2025-09-30 was $63.00K, a 1.61% increase year-over-year.
- IMMUNITYBIO, INC. other noncash income (expense) for fiscal 2025 was $250.00K.
- IMMUNITYBIO, INC. other noncash income (expense) for fiscal 2024 was -$1.15M.
- IMMUNITYBIO, INC. other noncash income (expense) for fiscal 2023 was -$8.93M.
- IMMUNITYBIO, INC. other noncash income (expense) for fiscal 2022 was -$11.75M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $62.00K 10-Q · filed 2026-08-04 | $125.00K derived: sum of 3 quarters · filed 2026-08-04 | $188.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $62.00K 10-Q · filed 2026-05-07 | $125.00K derived: sum of 2 quarters · filed 2026-05-07 | $188.00K derived: sum of 3 quarters · filed 2026-05-07 | $250.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $126.00K derived: sum of 2 quarters · filed 2026-02-23 | $188.00K derived: sum of 3 quarters · filed 2026-08-04 | $250.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $125.00K derived: sum of 2 quarters · filed 2026-08-04 | $187.00K 10-Q · filed 2025-11-05 | -$1.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $124.00K 10-Q · filed 2026-08-04 | -$1.21M derived: sum of 3 quarters · filed 2026-08-04 | -$1.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $62.00K 10-Q · filed 2026-05-07 | -$1.27M derived: sum of 2 quarters · filed 2026-05-07 | -$1.21M derived: sum of 3 quarters · filed 2026-05-07 | -$1.15M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.27M derived: sum of 2 quarters · filed 2026-02-23 | -$1.21M derived: sum of 3 quarters · filed 2026-02-23 | -$1.15M 10-K · filed 2026-02-23 |
| 2024-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $124.00K derived: sum of 2 quarters · filed 2025-11-05 | $187.00K 10-Q · filed 2025-11-05 | $250.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $125.00K 10-Q · filed 2025-08-05 | $188.00K derived: sum of 3 quarters · filed 2026-02-23 | -$3.77M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $63.00K 10-Q · filed 2025-05-12 | $126.00K derived: sum of 2 quarters · filed 2026-02-23 | -$3.84M derived: sum of 3 quarters · filed 2026-02-23 | -$6.36M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$3.90M derived: sum of 2 quarters · filed 2026-02-23 | -$6.42M derived: sum of 3 quarters · filed 2026-02-23 | -$8.93M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$6.48M derived: sum of 2 quarters · filed 2024-11-12 | -$8.99M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$5.03M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$2.50M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$11.75M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |